Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Conditions
Brief summary
This randomized phase III trial studies paclitaxel and trastuzumab with or without lapatinib to see how well they work in treating patients with stage II or stage III breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving paclitaxel with trastuzumab and/or lapatinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is not yet known which regimen is more effective in treating patients with breast cancer.
Detailed description
PRIMARY OBJECTIVE: I. To determine if the pathologic complete response (pCR) in the breast to neoadjuvant weekly paclitaxel with trastuzumab plus lapatinib (THL) is 20% greater than the pCR to weekly paclitaxel with trastuzumab alone (TH). SECONDARY OBJECTIVES: I. To determine the pathologic complete response in the breast and axilla, using American Joint Committee on Cancer (AJCC) Tumor, Lymph Nodes and Metastasis (TMN) criteria (version 6), to neoadjuvant weekly paclitaxel plus human epidermal growth factor 2 (HER2)- targeted therapy in patients with HER2-positive operable breast cancer. II. To evaluate residual cancer burden (RCB) as a predictor of long term relapse free survival (RFS) and overall survival (OS). III. To document the toxicity of all chemotherapeutic regimens (THL, TH). IV. To determine the correlation between clinical, radiographic and pathologic response. V. To compare overall survival (OS), relapse free survival (RFS) and time to first failure (TFF) among the treatment groups. VI. To obtain blood, fresh frozen and fixed tumor tissue to test specific hypotheses for which biomarker data exist and to evaluate biomarkers in blood, serum and tissue that are likely to influence response to and toxicity of trastuzumab alone or trastuzumab plus lapatinib, when given with paclitaxel. VII. To determine the surgical practice patterns for breast conservation and sentinel lymphadenectomy in patients undergoing neoadjuvant chemotherapy. VIII. To determine the radiotherapy practice patterns for post-mastectomy and regional nodal irradiation in patients undergoing neoadjuvant chemotherapy. IX. To evaluate pharmacogenomic determinants of toxicity. OUTLINE: Patients are randomized to 1 of 3 treatment arms. ARM I: Patients receive trastuzumab IV over 30-90 minutes and paclitaxel IV over 1 hour once weekly and lapatinib ditosylate orally (PO) once daily for 16 weeks in the absence of disease progression or unacceptable toxicity. ARM II: Patients receive trastuzumab and paclitaxel as in arm I. ARM III: Patients receive paclitaxel and lapatinib ditosylate as in arm I. (Discontinued as of 6-15-11) Within 42 days after completion of neoadjuvant therapy, patients in both arms undergo definitive surgery (breast conservation or total mastectomy). After completion of study treatment, patients are followed every 6 months for 2 years and then annually for up to 10 years.
Interventions
OTHERLaboratory Biomarker Analysis
Correlative studies
DRUGLapatinib Ditosylate
Given PO
DRUGPaclitaxel
Given IV
BIOLOGICALTrastuzumab
Given IV
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Pathologic confirmation of invasive breast cancer; patients with inflammatory breast cancer are not eligible * Clinical stage II-III operable invasive breast cancer with intent to perform surgical resection after neoadjuvant therapy * Patients with multicentric or bilateral disease are eligible as long as the target lesion meets the eligibility criteria for this study * Staging to rule out metastatic disease is recommended for clinical stage III patients * Tumors must be HER2 positive defined as HER2 3+ by immunohistochemical (IHC) assays or gene amplification by fluorescence in situ hybridization (FISH) with a ratio of \>= 2 on invasive tumor * Estrogen receptor (ER) and progesterone receptor (PgR) status must be known * The target lesion in the breast must be \>= 1 cm on physical examination or by radiographic measurement; palpable axillary adenopathy will be documented but not serve as measurable disease for the primary endpoint; patients with axillary disease only are not eligible to participate * Patient agrees to provide pretreatment biopsies * No prior chemotherapy, hormone therapy, biologic, or radiation therapy with therapeutic intent for this cancer * Cardiac ejection fraction must be \>= 50% by echocardiogram or multiple gated acquisition (MUGA) scan * Eastern Cooperative Oncology Group (ECOG) (Zubrod) performance status 0-1 * Patients must not be pregnant or nursing * Absolute neutrophil count (ANC) \>= 1,000/ul * Platelet count \>= 100,000/ul * Bilirubin =\< 1.5 times upper limit of normal * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 2.5 times upper limit of normal (ULN) * Serum beta-human chorionic gonadotropin (HCG) negative (in female patients unless status-post (s/p) hysterectomy or menopausal or no menses for 24 consecutive months); assay must have a sensitivity of at least 50 mIU/mL
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| pCR Rate | At time of surgery | Complete pathological response is defined as the absence of residual invasive carcinoma in the breast at the time of definitive surgical removal. Pathologic complete response in the lymph nodes is defined as no detectable invasive tumor by H\&E. Analysis will use a chi-square test for the difference in proportions of patients on the THL arm versus the TH arm who achieve a pCR. Exact binomial methods will be used to construct 95% confidence intervals around the pCR incidence for each arm. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pathologic Stage in the Breast and Axilla | At time of surgery | Stage will be determined by the American Joint Committee on Cancer (AJCC) TNM (tumor, lymph nodes, metastasis) staging system. yT0: No evidence of residual invasive primary tumor. yTis: Carcinoma in situ only (presence of ductal carcinoma in situ \[DCIS\] but completely free of invasive cancer). yT1: Residual invasive tumor \<= 2 in greatest dimension.yT2: Residual invasive tumor \> 2 cm but \<= 5 cm in greatest dimension.yT3: Residual invasive tumor \> 5 cm in greatest dimension.yT4: Residual tumor of any size with direct extension to the chest wall and/or skin (including ulceration or macroscopic nodules). |
| Radiographic Response Rate (at Completion of Neoadjuvant Therapy) | Week 16 | Response was defined by the Response Evaluation Criteria in Solid Tumors (RECIST). A responding participant had either a complete response (disappearance of all target lesions) or partial response (30% decrease in sum of longest diameter of target lesions). |
| Overall Survival Rate | Time from randomization to death or last follow-up (up to 10 years) | Overall survival was measured as the interval from study entry until death, from any cause, or last contact. Distribution was estimated using the Kaplan Meier product-limit method |
| Relapse-free Survival (RFS) Rate | Time from surgery to any recurrence (up to 10 years) | Relapse free survival is defined as the interval from definitive surgery to ipsilateral invasive breast tumor recurrence, regional invasive breast cancer recurrence, distant recurrence, or death from any cause, whichever occurs first. Patients who have not experienced any of these events will be censored at the date of last clinical assessment. Patients who do not undergo definitive surgery will not be assessable for RFS. Distribution was estimated using the Kaplan Meier product-limit method. Relapse-free survival (RFS) Rate is the rate of patients alive and relapse free. |
| Time to First Failure | Time from surgery to any recurrence (up to 10 years) | Time to first failure is defined as the interval from study entry to ipsilateral invasive breast tumor recurrence, regional invasive breast cancer recurrence, distant recurrence or death from any cause. Patients who have not experienced any of these events will be censored at the date of last clinical assessment. Distribution was estimated using the Kaplan Meier product-limit method. |
| Incidence of Adverse Events as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3 | Up to 30 days post-treatment | The type and grade of treatment-related toxicity will be tabulated by treatment arm. |
Countries
Puerto Rico, United States
Contacts
PRINCIPAL_INVESTIGATORLisa A Carey
Alliance for Clinical Trials in Oncology
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Arm I (THL) Patients receive trastuzumab 2 mg/kg IV over 30-90 minutes and paclitaxel 80 mg/m\^2 IV over 1 hour once weekly and lapatinib ditosylate 750 mg PO once daily for 16 weeks in the absence of disease progression or unacceptable toxicity. | 118 |
| Arm II (TH) Patients receive trastuzumab 2 mg/kg IV over 30-90 minutes and paclitaxel 80 mg/m\^2 IV over 1 hour once weekly for 16 weeks in the absence of disease progression or unacceptable toxicity. | 120 |
| Arm III (TL) Patients receive paclitaxel 80 mg/m\^2 IV over 1 hour once weekly and lapatinib ditosylate 15000 mg PO once daily for 16 weeks in the absence of disease progression or unacceptable toxicity. (Discontinued as of 6-15-11) | 67 |
| Total | 305 |
Baseline characteristics
| Characteristic | Arm II (TH) | Total | Arm I (THL) | Arm III (TL) |
|---|---|---|---|---|
| Age, Continuous | 50.3 years | 49.4 years | 48.5 years | 48.3 years |
| Clinical Stage Stage II | 80 participants | 209 participants | 81 participants | 48 participants |
| Clinical Stage Stage III | 40 participants | 96 participants | 37 participants | 19 participants |
| Hormone Receptor Status ER/PgR or Negative | 50 participants | 126 participants | 48 participants | 28 participants |
| Hormone Receptor Status ER/PgR Positive | 70 participants | 179 participants | 70 participants | 39 participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants | 2 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 8 Participants | 17 Participants | 4 Participants | 5 Participants |
| Race (NIH/OMB) Black or African American | 8 Participants | 27 Participants | 12 Participants | 7 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 2 Participants | 2 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 1 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 5 Participants | 13 Participants | 4 Participants | 4 Participants |
| Race (NIH/OMB) White | 97 Participants | 243 Participants | 95 Participants | 51 Participants |
| Region of Enrollment United States | 120 participants | 305 participants | 118 participants | 67 participants |
| Sex: Female, Male Female | 119 Participants | 303 Participants | 117 Participants | 67 Participants |
| Sex: Female, Male Male | 1 Participants | 2 Participants | 1 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| other Total, other adverse events | 114 / 115 | 114 / 115 | 64 / 65 |
| serious Total, serious adverse events | 15 / 115 | 12 / 115 | 6 / 65 |
Outcome results
Primary
pCR Rate
Complete pathological response is defined as the absence of residual invasive carcinoma in the breast at the time of definitive surgical removal. Pathologic complete response in the lymph nodes is defined as no detectable invasive tumor by H&E. Analysis will use a chi-square test for the difference in proportions of patients on the THL arm versus the TH arm who achieve a pCR. Exact binomial methods will be used to construct 95% confidence intervals around the pCR incidence for each arm.
Time frame: At time of surgery
Population: Participants who did not start protocol therapy or withdrew prior to surgery are excluded. Participants who did not undergo surgery are considered no having a pCR.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm I (THL) | pCR Rate | 56 percentage of participants |
| Arm II (TH) | pCR Rate | 46 percentage of participants |
| Arm III (TL) | pCR Rate | 32 percentage of participants |
p-value: 0.13Log Rank
p-value: 0.072Log Rank
Secondary
Incidence of Adverse Events as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3
The type and grade of treatment-related toxicity will be tabulated by treatment arm.
Time frame: Up to 30 days post-treatment
Secondary
Overall Survival
Overall survival was measured as the interval from study entry until death, from any cause, or last contact. Distribution was estimated using the Kaplan Meier product-limit method
Time frame: Time from randomization to death or last follow-up (up to 10 years)
Secondary
Pathologic Stage in the Breast and Axilla
Stage will be determined by the American Joint Committee on Cancer (AJCC) TNM (tumor, lymph nodes, metastasis) staging system.
Time frame: At time of surgery
Secondary
Radiographic Response Rate (at Completion of Neoadjuvant Therapy)
Response was defined by the Response Evaluation Criteria in Solid Tumors (RECIST). A responding participant had either a complete response (disappearance of all target lesions) or partial response (30% decrease in sum of longest diameter of target lesions).
Time frame: Week 16
Secondary
Relapse-free Survival (RFS)
Relapse free survival is defined as the interval from definitive surgery to ipsilateral invasive breast tumor recurrence, regional invasive breast cancer recurrence, distant recurrence, or death from any cause, whichever occurs first. Patients who have not experienced any of these events will be censored at the date of last clinical assessment. Patients who do not undergo definitive surgery will not be assessable for RFS. Distribution was estimated using the Kaplan Meier product-limit method.
Time frame: Time from surgery to any recurrence (up to 10 years)
Secondary
Time to First Failure
Time to first failure is defined as the interval from study entry to ipsilateral invasive breast tumor recurrence, regional invasive breast cancer recurrence, distant recurrence or death from any cause. Patients who have not experienced any of these events will be censored at the date of last clinical assessment. Distribution was estimated using the Kaplan Meier product-limit method.
Time frame: Time from study entry to any recurrence ( up to 10 years)